Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion
- Sponsor
- Bayer
- Study ID
- NCT02645747
- Status
- Completed
Conditions
- Retinal Vein Occlusion
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Aflibercept (Eylea, BAY86-5321) — DRUGEylea (intravitreal aflibercept) is an anti-Vascular Endothelial Growth Factor (VEGF) drug indicated for neovascular age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME) and visual impairment due to macular edema (ME) secondary to central or branched retinal vein occlusion (RVO). RVO, both branch and central, is the second most common type of retinal vascular disorders after diabetic retinal disease. Central retinal vein occlusion (CRVO) is characterized by an obstruction of the central retinal vein combined with variable amounts of retinal arterial insufficiency.
Study Details
The objective of this retrospective chart review is to evaluate drug utilization, usage patterns and indication of effectiveness Eylea in the routine clinical (real-life) management of patients who suffer from ME (Macular Edema), secondary to CRVO (Central Retinal Vein Occlusion), and who started treatment with Eylea for this indication.
Key Dates
- Start date
- Jan 21, 2016
- Status verified
- Sep 2018
- Primary completion
- Dec 23, 2017
- Completion
- Dec 23, 2017
Study Design
- Enrollment
- 126 participants (actual)
Arms
- Arm: Group 1The source population of this study is patients who suffer from visual impairment due to ME secondary to CRVO. In order to ensure the representativeness of the study population, the number of Belgian patients which started Eylea treatment during the brief period between the 1st of June 2014 and the 28th of February 2015 were taken into account. However, data of patients diagnosed with neovascular glaucoma secondary to CRVO will be excluded.
Primary Outcome Measure
Treatment duration [ Time Frame: At 12 months of treatment with Eylea ]
Related Studies
- National Eye Institute Biorepository for Retinal DiseasesRecruiting · National Eye Institute (NEI) · Bethesda, Maryland
- Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein SodiumEARLY_PHASE1 · Recruiting · MediBeacon · Ann Arbor, Michigan
- Optical Coherence Tomography Angiography in Subjects With Retinal Vascular DiseaseRecruiting · Johns Hopkins University · Baltimore, Maryland
- Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal InjectionsPHASE4 · Enrolling By Invitation · Harrow Inc · Tyler, Texas